PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS

Benzer Materyaller

• PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
  Yazar:: Rajshekhar Chakraborty, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
  Yazar:: Rajshekhar Chakraborty, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-11-01)
• Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101
  Yazar:: Michael Sang Hughes, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-10-01)
• A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
  Yazar:: Giovanni Palladini, ve diğerleri
  Baskı/Yayın Bilgisi: (2013-03-01)
• Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
  Yazar:: Claudia Bellofiore, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-03-01)